BeyondSpring (NASDAQ:BYSI) Stock Crosses Above 50 Day Moving Average – Should You Sell?
by Michael Walen · The Markets DailyBeyondSpring Inc. (NASDAQ:BYSI – Get Free Report)’s stock price passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.52 and traded as high as $1.73. BeyondSpring shares last traded at $1.71, with a volume of 2,351 shares.
Analyst Ratings Changes
Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of BeyondSpring in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.
Read Our Latest Research Report on BYSI
BeyondSpring Stock Down 0.9%
The company has a market cap of $70.32 million, a P/E ratio of -11.40 and a beta of 0.51. The firm’s 50-day moving average price is $1.52 and its 200-day moving average price is $1.74.
BeyondSpring (NASDAQ:BYSI – Get Free Report) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.49.
Institutional Trading of BeyondSpring
A hedge fund recently raised its stake in BeyondSpring stock. Geode Capital Management LLC lifted its position in BeyondSpring Inc. (NASDAQ:BYSI – Free Report) by 16.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 368,682 shares of the company’s stock after buying an additional 53,198 shares during the quarter. Geode Capital Management LLC owned approximately 0.91% of BeyondSpring worth $601,000 at the end of the most recent quarter. 40.29% of the stock is currently owned by institutional investors.
About BeyondSpring
BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.
The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.